var data={"title":"Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Karen J Tietze, PharmD</a></dd><dd><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Barry Fuchs, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Polly E Parsons, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Michael Avidan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Distress, due to pain, <span class=\"nowrap\">fear/anxiety,</span> dyspnea, or delirium is common among critically ill patients, especially those who are intubated or are having difficulty communicating with their caregivers [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/1\" class=\"abstract_t\">1</a>]. Distress may manifest clinically as agitation that is often associated with ventilator asynchrony and vital sign abnormalities. Regardless, distress needs to be treated to comfort the patient, ameliorate agitation that may interfere with supportive care, and attenuate increases in sympathetic tone, which may have untoward physiological effects [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Common sedative-analgesic medications used to treat distress in critically ill adults are reviewed here. Identifying the cause of distress and using this information to select the optimal sedative-analgesic agent is discussed separately. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;</a>.) </p><p>The management of pain and neuromuscular blockade in critically ill patients is also described separately. (See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;</a> and <a href=\"topic.htm?path=clinical-use-of-neuromuscular-blocking-agents-in-critically-ill-patients\" class=\"medical medical_review\">&quot;Clinical use of neuromuscular blocking agents in critically ill patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H970065\"><span class=\"h1\">ANALGESICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pain can be managed in the intensive care unit (ICU) with opioid analgesic and nonopioid analgesic agents. The choice of agent should be directed at the etiology of pain, but opioids are, in general, frequently administered for the management of pain in mechanically ventilated patients.</p><p class=\"headingAnchor\" id=\"H971743\"><span class=\"h2\">Opioid analgesics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">Morphine</a> sulfate, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, and <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> are the intravenous opioids that are most commonly used to manage distress due to pain in critically ill patients. Oral opioids such as <a href=\"topic.htm?path=oxycodone-drug-information\" class=\"drug drug_general\">oxycodone</a>, <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a>, and morphine are also given to patients where oral or enteral administration is preferred. <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> is also an option; advantages include its rapid onset of action and prompt clearance that are independent of hepatic and renal function, although there is debate as to whether its use is associated with a higher risk of tolerance [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p>All of the opioids lack amnestic properties, induce tolerance, and have similar analgesic and sedative properties when administered in equipotent doses [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/6\" class=\"abstract_t\">6</a>]. Specific agents differ in their onset, duration of action, histamine related side effects, and risk of accumulation in organ failure. The pharmacological properties of the opioids and principles for selection of intermittent, pre-procedural, continuous, and patient-controlled dosing are described in detail elsewhere. (See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H230414638\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Opioid analgesics'</a>.)</p><p>The Society of Critical Care Medicine (SCCM) 2013 guidelines place emphasis on the administration of intravenous opioids for non-neuropathic pain and analgesia-first sedation for the management of agitation in mechanically ventilated ICU patients [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"abstract_t\">7</a>]. The comparative advantages and disadvantages and typical dosage regimens, as well as the roles of analgesics, sedatives, anxiolytics, and antipsychotics in critically ill patients, are described in the table (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>). Dosing for obese patients is described separately. (See <a href=\"topic.htm?path=bariatric-surgery-intensive-care-unit-management-of-the-complicated-postoperative-patient\" class=\"medical medical_review\">&quot;Bariatric surgery: Intensive care unit management of the complicated postoperative patient&quot;</a>.)</p><p>Numerous drugs used commonly in the ICU have the potential to interact with opioids. Central nervous system (CNS) and respiratory depressants (eg, benzodiazepines) enhance the CNS and respiratory depressant effect of opioids, while CNS stimulants (eg, <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">methylphenidate</a>) decrease the CNS depressant effect of opioids. Other drug interactions are related to the metabolism of opioids via CYP3A4. As examples, the azole antifungals (eg, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>) and the macrolides and related antibiotics (eg, <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a>) may prolong <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> activity by inhibiting CYP3A4. The rifamycins (eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>) may decrease the serum concentration and effects of opioids.</p><p>The ultrashort-acting opioids, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> and <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>, are generally not used in critically ill patients because they do not offer advantages and may be more costly. The long-acting opioid agonist-antagonist analgesics are also not used very often because they are long-acting and may not produce sufficient analgesia due to ceiling effects. This class of agents includes <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">buprenorphine</a>, <a href=\"topic.htm?path=butorphanol-drug-information\" class=\"drug drug_general\">butorphanol</a>, dezocine, <a href=\"topic.htm?path=nalbuphine-drug-information\" class=\"drug drug_general\">nalbuphine</a>, and <a href=\"topic.htm?path=pentazocine-drug-information\" class=\"drug drug_general\">pentazocine</a>.</p><p class=\"headingAnchor\" id=\"H971750\"><span class=\"h2\">Nonopioid analgesics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">Acetaminophen</a> (enteral or intravenous), nonsteroidal antiinflammatory agents (NSAIDs) and intravenous <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> can be used as alternatives or additives to opioids for the management of non-neuropathic pain in the ICU (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>). Additionally, they can be used as opioid-sparing agents to reduce or eliminate the need for opioids in adult ICU patients [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"abstract_t\">7</a>]. Enteral <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a>, <a href=\"topic.htm?path=pregabalin-drug-information\" class=\"drug drug_general\">pregabalin</a>, <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, in addition to intravenous opioids, can be used to treat neuropathic pain in adult ICU patients [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H697575272\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Nonopioid analgesics'</a>.)</p><p class=\"headingAnchor\" id=\"H970645\"><span class=\"h1\">PROPOFOL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is an intravenous anesthetic that is commonly used for sedation of the agitated adult intensive care unit (ICU) patient. It is particularly useful when rapid sedation and rapid awakening is desirable (eg, patients who require frequent neurological examinations) because it has a short duration of effect. In one large, randomized, open label trial, compared to intermittent bolus <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> (median dose 11.5 <span class=\"nowrap\">mg/day),</span> propofol infusions with daily interruption (mean dose 24.4 &plusmn; 16.3 <span class=\"nowrap\">mcg/kg/min)</span> resulted in significantly lower number of mechanical ventilation days but did require higher <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> doses per ventilator day [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/8\" class=\"abstract_t\">8</a>]. A multicenter ICU database analysis of over 3000 patients reported that, when compared with <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> or lorazepam, propofol infusions were associated with a lower mortality (risk ratio 0.76 and 0.78, respectively), earlier discharge, and discontinuation from mechanical ventilation [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/9\" class=\"abstract_t\">9</a>]. Data from comparative trials with current sedation guidelines are needed to confirm these results. &#160;</p><p class=\"headingAnchor\" id=\"H970847\"><span class=\"h2\">Mechanism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Activation of the central gamma-aminobutyric acid receptors (GABA[A] receptors) with modulation of hypothalamic sleep pathways appear to be the mechanism by which <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> exerts it&rsquo;s effect [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/10-13\" class=\"abstract_t\">10-13</a>].</p><p class=\"headingAnchor\" id=\"H970854\"><span class=\"h2\">Properties</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is a highly lipophilic phenol derivative that is insoluble in water. Therefore, it is formulated as an emulsion of soybean oil, egg lecithin, and glycerol for intravenous administration. Although labeled contraindications include hypersensitivity to eggs, egg products, soy, or soy products, reviews suggest a need for further evaluation of this issue [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/14,15\" class=\"abstract_t\">14,15</a>]. Propofol has amnesic, anxiolytic, anticonvulsant, and muscle relaxant effects. It has no direct analgesic effects.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Onset of action &ndash; <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> has an onset of action of less than one minute because its high lipophilicity facilitates passage through the blood-brain barrier.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of effect &ndash; <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a>'s duration of effect is 3 to 10 minutes during short-term use (&lt;48 hours). The short duration reflects the rapid metabolism of propofol by the liver and elsewhere to minimally active metabolites, which are renally excreted. Less is known about propofol's duration of effect following long-term administration. One study reported an elimination half-life of 31 hours after prolonged administration, suggesting that propofol's high lipophilicity leads to its accumulation in fatty tissues and prolonged sedation [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/16\" class=\"abstract_t\">16</a>]. These data, however, may overestimate the magnitude of the sedative prolongation. Another study, found that when compared to patients receiving short term sedation with propofol (&lt;24 hours), the mean recovery time to extubation in those that received propofol for extended periods categorized as medium (1 to 7 days, n = 16) and long term (&gt;7 days; n = 10) was delayed by only 10 and 30 minutes, respectively [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p>The elimination of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> is not impaired by hepatic or renal dysfunction. Propofol has a large volume of distribution and is highly protein bound.</p><p class=\"headingAnchor\" id=\"H970861\"><span class=\"h2\">Dosage regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A typical dosage regimen for <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> is listed in the table (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>). A loading dose of 5 <span class=\"nowrap\">mcg/kg/min</span> over five minutes is recommended in the Society of Critical Care Medicine (SCCM) 2013 guidelines only for patients not at risk for hypotension [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"abstract_t\">7</a>]. </p><p class=\"headingAnchor\" id=\"H970868\"><span class=\"h2\">Administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is administered by continuous infusion in the ICU and not by intermittent infusion because it is associated with dose- and rate-dependent hypotension. This was best illustrated by an observational study of 25,981 patients receiving propofol anesthesia, 4079 patients (15.7 percent) developed hypotension, defined as a systolic blood pressure &lt; 90 mmHg [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/18\" class=\"abstract_t\">18</a>]. Among those who became hypotensive, 77 percent of the hypotensive episodes occurred within 10 minutes of induction via a bolus infusion.</p><p>The manufacturer recommends that the bottles and tubing be discarded every twelve hours and that line integrity be maintained in order to minimize the risk of bacterial contamination.</p><p>When administered peripherally, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> is generally given through a large bore intravenous catheter (often in the antecubital fossa) to reduce burning, stinging, and pain that can occur with peripheral administration.</p><p>During administration, routine biochemical monitoring (triglycerides, serum lactate, creatine, kinase, myoglobin) may allow early identification of the <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion syndrome (PRIS) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/19\" class=\"abstract_t\">19</a>]. Propofol should be discontinued as soon as any abnormality is identified. &#160;</p><p class=\"headingAnchor\" id=\"H970875\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypotension is a common consequence of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion, estimated to occur in approximately 25 percent of ICU patients who receive propofol for sedation [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/20\" class=\"abstract_t\">20</a>]. Other potential adverse effects of propofol which are uncommon include bradycardia, arrhythmias, neuroexcitatory effects (seizure-like activity, myoclonus, choreoathetoid movements, meningismus), infections from contaminated vials or tubing, respiratory acidosis, pancreatitis, hypertriglyceridemia, anaphylaxis, and green or white discoloration of urine [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/16,21-24\" class=\"abstract_t\">16,21-24</a>].</p><p>Unusual and potentially serious complications are associated with continuous infusion of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> for longer than 24 to 48 hours. These include progressive hypertriglyceridemia, pancreatitis, increased carbon dioxide production, and an excessive caloric load (the emulsion contains approximately 1.1 <span class=\"nowrap\">kcal/mL,</span> most of which is derived from lipids). Despite these complications, continuous infusion of propofol for greater than 24 hours does not appear to increase overall mortality, according to a meta-analysis of 14 randomized trials (1184 patients) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H970882\"><span class=\"h3\">Propofol infusion syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PRIS is a rare complication of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion. It is generally associated with high doses (&gt;4 <span class=\"nowrap\">mg/kg</span> per hour or &gt;67 <span class=\"nowrap\">mcg/kg</span> per minute) and prolonged use (&gt;48 hours) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/26-28\" class=\"abstract_t\">26-28</a>] though it has been reported with high-dose short-term infusions [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Additional proposed risk factors include a young age, critical illness, high fat and low carbohydrate intake, inborn errors of mitochondrial fatty acid oxidation, and concomitant catecholamine infusion or steroid therapy [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/30\" class=\"abstract_t\">30</a>]. Characteristics of PRIS include acute refractory bradycardia, severe metabolic acidosis, cardiovascular collapse, rhabdomyolysis, hyperlipidemia, renal failure, and hepatomegaly [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/27,31\" class=\"abstract_t\">27,31</a>].</p><p>The incidence of PRIS is unknown, but it is probably less than 1 percent [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/32\" class=\"abstract_t\">32</a>]. Mortality is variable but high (33 to 66 percent) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/27,33,34\" class=\"abstract_t\">27,33,34</a>]. Treatment involves discontinuation of the <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion and supportive care [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H970925\"><span class=\"h3\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Central nervous system (CNS) and respiratory depressants (eg, opioid narcotics, sedatives) enhance the CNS and respiratory depressant effect of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>. Propofol undergoes hepatic conjugation to inactive metabolites; thus, metabolically-related drug interactions of major clinical importance have not been identified. Co-administration of propofol with <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> increases the risk of opisthotonus <span class=\"nowrap\">and/or</span> grand mal seizures.</p><p class=\"headingAnchor\" id=\"H1252258399\"><span class=\"h1\">FOSPROPOFOL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fospropofol is a water-soluble <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> prodrug approved by the US Food and Drug Administration (FDA) for monitored anesthesia care (MAC) sedation in adults undergoing diagnostic or therapeutic procedures [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/35\" class=\"abstract_t\">35</a>]. Fospropofol is metabolized by alkaline phosphatases to propofol, formaldehyde, and phosphate. The formaldehyde is then metabolized by tissue enzymes to formate, which is oxidized to carbon dioxide. </p><p>In an open-label multicenter trial, 60 mechanically ventilated medical or surgical patients were randomly assigned to receive fospropofol by IV bolus plus infusion, fospropofol by infusion only, or <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> by infusion only for up to twelve hours [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/36\" class=\"abstract_t\">36</a>]. All three groups were permitted an increased infusion rate for agitation. Fospropofol was well-tolerated and effective for short-term sedation. &#160;</p><p class=\"headingAnchor\" id=\"H970932\"><span class=\"h1\">DEXMEDETOMIDINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">Dexmedetomidine</a> is a highly selective, centrally acting alpha-2-agonist with anxiolytic, sedative, and some analgesic effects. It has no deleterious effects on respiratory drive. According to the approved product information from the US Food and Drug Administration (FDA), dexmedetomidine is indicated for initial sedation of mechanically ventilated patients for up to 24 hours. The rationale for the 24 hour limit is that longer use may increase the risk of withdrawal effects (eg, hypertension), although these effects have not been consistently found in studies [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/37,38\" class=\"abstract_t\">37,38</a>].</p><p><a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">Dexmedetomidine</a> may reduce the <strong>duration of mechanical ventilation and intensive care unit (ICU) stay</strong> when compared with traditional sedatives in the ICU [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/39-46\" class=\"abstract_t\">39-46</a>]. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A meta-analysis of seven studies totaling 1624 patients reported a mean reduction in duration of mechanical ventilation by 22 percent and length of stay by 14 percent [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/39\" class=\"abstract_t\">39</a>]. However, the quality of evidence ranged from low to very low, limiting interpretation of the analysis. The seven studies included medical and surgical patients and patients with low to moderate risk of mortality.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When compared with <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, two studies suggest that <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> decreased the duration of mechanical ventilation (SEDCOM: 3.7 versus 5.6 days; MIDEX: 5.1 versus 6.8 days, respectively), but had no effect of length of ICU stay [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40-42\" class=\"abstract_t\">40-42</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When compared with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, one large randomized study of a mixed population of critically-ill patients showed no effect (PRODEX) on the duration of mechanical ventilation [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40\" class=\"abstract_t\">40</a>]. Smaller observational studies have shown mixed effects [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/43,46,47\" class=\"abstract_t\">43,46,47</a>]; as an example, one study of postoperative patients reported a significant reduction in mechanical ventilation hours (median time to extubation 5 versus 10 hours) and another study of a mixed population of critically ill patients reported an increased length of stay in those on <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> (four versus two days) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/43,46\" class=\"abstract_t\">43,46</a>]. &#160;</p><p/><p>Similarly, data reporting the effects of <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> on <strong>delirium </strong>are mixed:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While one meta-analysis and two systematic reviews, several randomized trials, and observational studies reported a reduction in the risk or duration of delirium, several additional randomized studies reported no benefit, when compared with other sedative agents in the ICU [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/39-41,48-54\" class=\"abstract_t\">39-41,48-54</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another trial of a mixed population of 71 ICU patients, in whom agitated delirium was prohibiting extubation (DahLIA), reported that compared to the addition of a placebo, the addition of <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> to standard sedation (mostly <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>) resulted in an increase in ventilator-free hours at seven days (145 versus 128 hours) as well as reduced time to extubation (22 versus 44 hours) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p>No conclusive mortality benefit has been reported from the use of <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> in critically ill patients. Although dexmedetomidine has been associated with a small decrease in postoperative mortality in patients undergoing cardiac surgery, another meta-analysis of seven trials reported no survival advantage associated with its use [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/39,49\" class=\"abstract_t\">39,49</a>]. In another randomized trial of 201 mechanically ventilated patients with sepsis, compared with standard sedation (with <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>), dexmedetomidine did not result in any mortality benefit or increase in ventilator-free days despite a higher rate of well-controlled sedation [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/47\" class=\"abstract_t\">47</a>]. However, the study was powered to detect a 20 percent difference in mortality, and consequently may have been unable to detect smaller differences in mortality. &#160; &#160;</p><p><a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">Dexmedetomidine</a> may decrease the need for alternative sedatives especially in patients withdrawing from alcohol, the details of which are discussed separately [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/55,56\" class=\"abstract_t\">55,56</a>]. (See <a href=\"topic.htm?path=management-of-moderate-and-severe-alcohol-withdrawal-syndromes#H23\" class=\"medical medical_review\">&quot;Management of moderate and severe alcohol withdrawal syndromes&quot;, section on 'Alternative and contraindicated agents'</a>.)</p><p><a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">Dexmedetomidine</a> may be more cost-effective than other sedatives. As an example, sedation with dexmedetomidine lowered ICU costs compared with standard care; cost savings were achieved primarily by reducing the duration of total ICU stay without prolonging post-ICU hospitalization [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/45\" class=\"abstract_t\">45</a>]. &#160;</p><p>Transitioning from <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> to oral <a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">clonidine</a> may be a safe and cost-effective way to continue sedation with a centrally acting alpha-2-agonist in patients who are hemodynamically stable and have a functional gastrointestinal tract [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/57\" class=\"abstract_t\">57</a>]. In a single-center prospective observational pilot study, 15 of 20 patients were successfully transitioned from dexmedetomidine to clonidine [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/57\" class=\"abstract_t\">57</a>]. Dexmedetomidine and clonidine dosages were titrated during the transition period; maintenance clonidine dosages ranged from 0.2 to 0.5 mg every six hours and were adjusted to achieve target sedation levels [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H971134\"><span class=\"h2\">Dosage regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An initial loading dose is typically not performed but can be administered if necessary [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/58\" class=\"abstract_t\">58</a>]. The initial loading dose may cause transient hypotension or hypertension, depending upon whether vasodilation from activation of central alpha 2a receptors or vasoconstriction from activation of peripheral alpha 2b receptors predominates.</p><p>The usual <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> maintenance dose is 0.2 to 0.7 <span class=\"nowrap\">mcg/kg/hour,</span> with dosage increases no more frequently than every 30 minutes. Use of higher doses (up to 1.5 <span class=\"nowrap\">mcg/kg/hr)</span> has been reported [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/41,48\" class=\"abstract_t\">41,48</a>]. However, doses &gt;1.5 <span class=\"nowrap\">mcg/kg/hr</span> do not appear to add to dexmedetomidine's clinical efficacy [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/59\" class=\"abstract_t\">59</a>]. The variability in patient response to dexmedetomidine may be due to as yet unidentified patient characteristics, pharmacokinetics, and genetic polymorphisms [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/60\" class=\"abstract_t\">60</a>]. &#160; </p><p>There are no specific guidelines for modifying the dose for elderly patients or patients who have renal or hepatic impairment. It is prudent to start at the low end of the dosage range and titrate slowly based upon the patient's response.</p><p>The advantages, disadvantages, role, and dosage regimen of <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> are described in the table (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H971141\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential adverse events during sedation with <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> include hypotension [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40\" class=\"abstract_t\">40</a>], hypertension, nausea, bradycardia [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40\" class=\"abstract_t\">40</a>], and atrial fibrillation. Refractory cardiogenic shock has also been reported [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H971148\"><span class=\"h3\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> is metabolized by glucuronidation and cytochrome P450, clinically important cytochrome P450-mediated drug interactions have not been identified. Drugs that lower systemic blood pressure may enhance dexmedetomidine's hypotensive effect, while drugs that increase systemic blood pressure may enhance dexmedetomidine's hypertensive effect.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BENZODIAZEPINES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> and <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> are the benzodiazepines that are best suited for sedation in the intensive care unit (ICU) because they can be administered by either intermittent or continuous infusion and have a relatively short duration of effect. Intravenous <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> is used less often to sedate patients in the ICU. It can be administered by intermittent infusion, but not continuous infusion.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Mechanism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Benzodiazepines bind to specific receptors in the gamma aminobutyric acid (GABA) receptor complex, which enhances the binding of this inhibitory neurotransmitter [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/62\" class=\"abstract_t\">62</a>]. Anxiolysis is achieved at low doses. Higher doses are associated with sedation, muscle relaxation, anterograde amnesia, anticonvulsant effects, and both respiratory and cardiovascular depression. Coadministration with an opioid analgesic may potentiate respiratory and cardiovascular depression.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Properties</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The benzodiazepines are equally efficacious if they are administered in equipotent doses, but they differ in potency, rapidity of action, and duration of effect.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potency &ndash; A benzodiazepine's potency is determined by its binding affinity for the GABA receptor. <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">Lorazepam</a> has the highest binding affinity and the greatest potency. <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> have progressively lower binding affinities and potencies [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapidity of action &ndash; A benzodiazepine's rapidity of action is related to how quickly it crosses the blood-brain barrier. <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> readily cross the blood-brain barrier because they are the highly lipophilic. Midazolam has an onset of action of 2 to 5 minutes following intravenous infusion and diazepam has a nearly immediate onset of action. <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">Lorazepam</a> is less lipophilic and, therefore, has a slower onset of action of 5 to 20 minutes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of effect &ndash; The duration of effect soon after initiating intermittent infusions differs from the duration of effect following repeated dosing. Initially, lipophilic benzodiazepines have a short duration of effect because there is rapid redistribution from the central nervous system to peripheral tissue sites. With repeated dosing, however, all benzodiazepines accumulate in adipose tissue. This increases the duration of effect because there is more drug that needs to be mobilized for elimination, particularly if a large cumulative dose was administered. Obese patients may store more drug than lean patients and are at greater risk for prolonged benzodiazepine effects. A drug's duration of effect is also influenced by the presence of active metabolites, patient factors (ie, age, body weight, hepatic function, renal function), drug interactions, and the mechanism of metabolism.</p><p/><p><a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> has a short duration of effect (2 to 4 hours) when it is given short-term (&lt;48 hours) by intermittent infusion to a patient with intact hepatic function because it has rapid hepatic clearance and there is rapid redistribution to peripheral tissue sites. Midazolam may cause prolonged sedation if it is administered over a longer duration because it has a large volume of distribution, binds to peripheral tissues, and has an active metabolite (alpha-hydroxymidazolam) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/64\" class=\"abstract_t\">64</a>]. The active metabolite is most likely to accumulate in patients who have poor hepatic or renal function or who are receiving medications that inhibit CYP3A4 metabolism (eg, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, macrolide antibiotics, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>).</p><p><a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">Lorazepam</a> has a moderate duration of effect (6 to 8 hours) when it is administered short-term (&lt;48 hours) by intermittent infusion. This duration of effect reflects lorazepam's low hepatic clearance, small volume of distribution, and absence of active metabolites [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/65\" class=\"abstract_t\">65</a>]. Lorazepam is a good choice for longer-term sedation because it has a low risk of drug interactions and its metabolism does not form active metabolites [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/66\" class=\"abstract_t\">66</a>].</p><p><a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">Diazepam</a> has a short duration of effect (30 to 60 minutes) when it is administered short-term (&lt;48 hours) by intermittent infusion. This duration of effect reflects diazepam's rapid redistribution to peripheral tissue sites and hepatic clearance. Diazepam may cause prolonged sedation with repeated dosing because it has a large volume of distribution and it has two active metabolites (desmethyldiazepam and methyloxazepam). These active metabolites are most likely to accumulate in patients who are old, obese, or have renal or hepatic dysfunction.</p><p>Tolerance (the need for an increased dose to achieve the same effect with continued administration) occurs with all benzodiazepines. It may reflect changes in the volume of distribution or in the density, binding affinity, <span class=\"nowrap\">and/or</span> occupancy of the benzodiazepine receptor.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The comparative advantages and disadvantages, as well as the roles of <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a>, and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> in critically ill patients, are described in the table (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Dosage regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Typical dosage regimens for <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a>, and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> are listed in the table (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>). Dosing for obese patients is described separately. (See <a href=\"topic.htm?path=bariatric-surgery-intensive-care-unit-management-of-the-complicated-postoperative-patient\" class=\"medical medical_review\">&quot;Bariatric surgery: Intensive care unit management of the complicated postoperative patient&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Adverse effects</span></p><p class=\"headingAnchor\" id=\"H91918874\"><span class=\"h3\">General</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Respiratory and cardiovascular depression are well known dose-dependent complications of benzodiazepines. &#160;</p><p>Excess sedation due to the accumulation of drug in adipose tissue can also occur as a consequence of sedation with benzodiazepines. Pharmacokinetically, this is more likely among patients who are sedated with benzodiazepines for longer than 48 hours or on continuous infusions [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/67\" class=\"abstract_t\">67</a>]. </p><p>Benzodiazepines, particularly infusions, can increase the risk for delirium in critically ill patients [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/48,68-72\" class=\"abstract_t\">48,68-72</a>]. In an observation study of 198 mechanically ventilated patients receiving pharmacological sedation, <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> was identified as an independent risk factor for delirium [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/68\" class=\"abstract_t\">68</a>]. Delirium appears to be more common among those who receive deep sedation (even if the deep sedation is for a short duration), are older, or have dementia [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/69,71\" class=\"abstract_t\">69,71</a>]. Three studies indicated that, compared to <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a>, the administration of <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> resulted in a higher prevalence of delirium (SEDCOM: 77 versus 54 percent; MIDEX: visual assessment scale score difference of 19.7 in favor of dexmedetomidine; and MENDS trial: 7 versus 3 days without delirium or coma) without any change in length of ICU stay [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40,41\" class=\"abstract_t\">40,41</a>] or mortality [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40\" class=\"abstract_t\">40</a>]. </p><p>Patients may rarely have a paradoxical reaction to benzodiazepines. This is characterized by agitation, restlessness, and hostility [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/73\" class=\"abstract_t\">73</a>]. Increasing the dose may worsen the agitation. The most appropriate management is to discontinue the benzodiazepine and sedate the patient with an alternative sedative. <a href=\"topic.htm?path=flumazenil-drug-information\" class=\"drug drug_general\">Flumazenil</a> has been reported to reverse the paradoxical reaction [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/74,75\" class=\"abstract_t\">74,75</a>].</p><p>Intravenous <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> may increase the risk of venous thrombosis and phlebitis at the injection site [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/76\" class=\"abstract_t\">76</a>]. The latter can cause injection site pain.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Propylene glycol toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Propylene glycol is the carrier (solvent) that is used to administer intravenous <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> or <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a>. Infusion of either drug may be complicated by propylene glycol toxicity [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/77-80\" class=\"abstract_t\">77-80</a>].</p><p>Propylene glycol toxicity is characterized by hyperosmolarity and an anion gap metabolic acidosis, which is often accompanied by acute kidney injury and can progress to multisystem organ failure, if severe [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/77-80\" class=\"abstract_t\">77-80</a>]. It can occur with normal doses and renal function, but it is usually associated with dosages above the recommended range of 0.1 <span class=\"nowrap\">mg/kg/hour</span> <span class=\"nowrap\">and/or</span> renal impairment [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/79,81,82\" class=\"abstract_t\">79,81,82</a>]. An osmolar gap &gt;10 <span class=\"nowrap\">mmoles/L</span> suggests that the serum propylene glycol concentration is high enough to cause toxicity [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/83\" class=\"abstract_t\">83</a>]. Treatment consists of discontinuing the offending agent and, if severe, dialysis [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/80\" class=\"abstract_t\">80</a>].</p><p>Propylene glycol is not the solvent for intravenous <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>. Therefore, patients who receive intravenous midazolam are not at risk for propylene glycol toxicity.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerous drugs used commonly in the ICU may interact with benzodiazepines. Some increase the benzodiazepine effect, while others decrease the effect.</p><p>Central nervous system (CNS) and respiratory depressants (eg, opioids) enhance the CNS and respiratory depressant effect of benzodiazepines. Conversely, CNS stimulants (eg, <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">methylphenidate</a>) decrease the CNS depressant effect of benzodiazepines. Many other drug interactions are related to the metabolism of benzodiazepines via the cytochrome P450 system:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> is susceptible to interactions with drugs that either inhibit or induce CYP3A4, since CYP3A4 hydroxylates midazolam to two active metabolites, 1-hydroxy-midazolam and 3-hydroxy-midazolam. As examples, the azole antifungals (eg, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>) and the macrolides and related antibiotics (eg, <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a>) may prolong midazolam activity by inhibiting CYP3A4. Conversely, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> may decrease midazolam activity by inducing CYP3A4. Rifamycins (eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>) may decrease midazolam activity by increasing cytochrome P450-mediated oxidative metabolism. Hydantoins (eg, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a>) may increase midazolam clearance and midazolam inhibits hydantoin clearance; the latter leads to increased serum concentrations of the hydantoins.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">Diazepam</a> is susceptible to interactions with many of the same drugs that inhibit or induce cytochrome P450 because it is hydroxylated by CYP3A4 to <a href=\"topic.htm?path=temazepam-drug-information\" class=\"drug drug_general\">temazepam</a> and N-demethylated by CYP3A4 and CYP2C19 to desmethyldiazepam. Temazepam and desmethyldiazepam are active metabolites that are subsequently metabolized to another active metabolite, <a href=\"topic.htm?path=oxazepam-drug-information\" class=\"drug drug_general\">oxazepam</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">Lorazepam</a> does not interact with drugs that inhibit or induce cytochrome P450 because it undergoes extensive glucuronidation in the liver to an inactive 3-O-phenolic metabolite.</p><p/><p class=\"headingAnchor\" id=\"H2957373\"><span class=\"h1\">KETAMINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is rarely used and is not approved for use in the adult intensive care unit (ICU) population. Ketamine is an intravenous anesthetic agent with analgesic and bronchodilator properties in subanesthetic doses. Unlabeled uses include procedural <span class=\"nowrap\">sedation/analgesia</span> and as an adjunct to opioid analgesia for non-neuropathic pain [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"abstract_t\">7</a>]. </p><p><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> noncompetitively blocks glutamate N-methyl-D-aspartate (NMDA) receptors within sensory nerve endings; other pharmacologic actions at sub-anesthetic dosages have been identified, including opioid, muscarinic, and nicotinic receptor blockade [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/84\" class=\"abstract_t\">84</a>]. </p><p>Due to its lipid solubility, an IV bolus dose of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> is active within one minute with a duration of action of 10 to 15 minutes. Ketamine is metabolized in the liver through several cytochrome systems to several metabolites, including the weakly active metabolite norketamine, that are cleared by the kidneys. &#160;</p><p><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> produces a &quot;dissociated anesthesia&quot; wherein patients remain conscious with spontaneous breathing and intact brain stem reflexes. By stimulating the sympathetic nervous system there is less cardiovascular depression; this preserves and sometimes increases blood pressure, making it an attractive agent for use in patients in shock or with frank hypotension. Ketamine also has mild bronchodilatory activity such that it has been anecdotally used for sedation in patients with status asthmaticus.</p><p>The use of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> is limited by its psychoactive effects (vivid hallucinations, confusion, and delirium). Hallucinations or delirium may also occur during recovery from ketamine. Ketamine is contraindicated in patients with known hypersensitivity to it and in patients at risk from potentially significant elevations in blood pressure. Other significant adverse reactions include excessive salivation and respiratory and cardiac depression. &#160;</p><p>Small randomized studies of patients with burns suggest that during painful procedures (eg, dressing changes), oral <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> provides better analgesia than <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> or the combination of <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a>, and <a href=\"topic.htm?path=codeine-drug-information\" class=\"drug drug_general\">codeine</a> during painful procedures (eg, dressing changes) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/85,86\" class=\"abstract_t\">85,86</a>]. Another review suggested a reduction in opioid consumption postoperatively [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/87\" class=\"abstract_t\">87</a>]. Data from well-designed randomized controlled trials are needed to determine the role of ketamine in procedural <span class=\"nowrap\">sedation/analgesia</span> and ICU analgesia. &#160;</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">ANTIPSYCHOTICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antipsychotics can be used in the intensive care unit (ICU) for the treatment of hyperactive delirium. <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> can be administered intravenously, has a mild sedative effect, and has relatively low cardiorespiratory depressive effects. Despite its widespread use for the treatment of delirium in the ICU, there is no published evidence supporting a reduction in the duration of mechanical ventilation by haloperidol and the 2013 Society of Critical Care Medicine (SCCM) guidelines, compared to the 2002 guidelines, make no recommendation favoring its use over other anti-psychotics for the management of delirium in adult ICU patients [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"abstract_t\">7</a>]. </p><p>Atypical antipsychotics (<a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>) have also been used in adult ICU patients to treat delirium. While there is some evidence that the oral atypical antipsychotics improve delirium in critically ill patients [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/88,89\" class=\"abstract_t\">88,89</a>], there is a paucity of studies that examine outcome or compare the efficacy and safety of oral atypical antipsychotics to <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> and to one another. The few studies that exist suggest that the efficacy and safety of oral atypical antipsychotics may be similar to that of haloperidol [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/88,90,91\" class=\"abstract_t\">88,90,91</a>]. In a retrospective review of 156 adult patients admitted to an ICU and treated with an atypical antipsychotic for management of delirium, 31 percent developed QTc prolongation; 24 percent had a QTc greater than 500 msec [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/92\" class=\"abstract_t\">92</a>].</p><p>Although <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> and atypical antipsychotics can be used, further studies are necessary to validate the role of haloperidol or oral atypical antipsychotics, such as <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, as effective therapies to reduce the duration of mechanical ventilation in adult ICU patients. </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Mechanism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> and the other neuroleptics antagonize dopamine and other neurotransmitters. However, their precise mechanism of action remains unknown.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Properties</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> causes dose-dependent sedation. It tends to be less sedating and have less anticholinergic activity than other neuroleptics.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapidity of onset &ndash; <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> has an onset of action 15 to 20 minutes after intravenous infusion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of effect &ndash; <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a>'s duration of effect varies and depends upon the cumulative dose. Generally speaking, re-dosing may be needed 4 to 12 hours after symptoms have been controlled with the initial doses.</p><p/><p><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> is highly protein bound, has a large volume of distribution, is metabolized hepatically by CYP3A4, CYP2D6, and glucuronidation; the hydroxymetabolite (reduced haloperidol) is active [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/93\" class=\"abstract_t\">93</a>]. The pyridinium metabolite, a structural analogue of a known neurotoxin, may be neurotoxic [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/94\" class=\"abstract_t\">94</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Dosage regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The administration of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> intravenously is common, but it has not been approved by the US Food and Drug Administration (FDA). The reason that it has not been approved is that intravenous administration may have a greater risk of serious adverse events than oral or intramuscular administration, most notably torsades de pointes and sudden cardiac death [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/95\" class=\"abstract_t\">95</a>].</p><p>Numerous dosing regimens have been used for the treatment of delirium in adult ICU patients, none of which have been validated. Continuous infusions (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>) are rarely indicated but studies suggest that they are probably safe and effective [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/96-98\" class=\"abstract_t\">96-98</a>]. Most commonly used regimens are:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2.5 to 5 mg intravenous bolus doses administered every six hours, as needed (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/99\" class=\"abstract_t\">99</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An initial dose determined by the severity of the agitation. Examples include a 0.5 to 2 mg intravenous bolus dose for mild agitation, a 2 to 5 mg intravenous bolus dose for moderate agitation, and a 10 to 20 mg intravenous bolus dose for severe agitation. Following the initial dose, escalate the dose as needed until calm is achieved [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/100\" class=\"abstract_t\">100</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A continuous <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> infusion beginning at a dose of 10 <span class=\"nowrap\">mg/h</span> and then increasing 5 <span class=\"nowrap\">mg/hr</span> every thirty minutes as needed until calm is achieved [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/96\" class=\"abstract_t\">96</a>]. [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/96-98\" class=\"abstract_t\">96-98</a>]</p><p/><p>Once calm is restored, a maintenance dose is desirable unless it appears that the delirium may quickly resolve. A reasonable approach to maintenance dosing is to administer 25 percent of the total loading dose every six hours (<a href=\"image.htm?imageKey=PULM%2F79667\" class=\"graphic graphic_table graphicRef79667 \">table 1</a>).</p><p>The safe maximum daily dose of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> is not known. There are case reports of doses as high as 945 <span class=\"nowrap\">mg/day</span> [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/96,101\" class=\"abstract_t\">96,101</a>]. Doses greater than 200 <span class=\"nowrap\">mg/day</span> have been safely administered for up to 15 consecutive days [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/96,100\" class=\"abstract_t\">96,100</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Haloperidol-associated polymorphic ventricular tachycardia (including torsades de pointes) is an uncommon but severe adverse reaction [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/102,103\" class=\"abstract_t\">102,103</a>]. It is primarily associated with intermittent high dose intravenous administration and prolonged QTc interval. When intermittent <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> infusions are used, the QT interval should be monitored every shift (ie, every 8 to 12 hours) and haloperidol should not be given if the corrected QT interval exceeds 500 msec. (See <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology#H4\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;, section on 'Medications'</a>.)</p><p>Other potential side effects of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> include acute dystonic reactions, parkinsonism, tardive dyskinesia, akathisia, and neuroleptic malignant syndrome. For unclear reasons, extrapyramidal side effects are less common among patients receiving intravenous haloperidol than among those receiving oral haloperidol [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/104\" class=\"abstract_t\">104</a>].</p><p>Elderly patients with dementia may have an increased risk of cardiovascular-related death (due to heart failure or sudden cardiac death) or infection-related death (due to pneumonia) when treated with atypical or typical antipsychotics. This was illustrated by a meta-analysis of 15 randomized trials (5204 patients) that found that older patients with dementia who were treated with atypical antipsychotics had an increased risk of death compared to those who received placebo (3.5 versus 2.2 percent, OR 1.54, 95% CI 1.06-2.23) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/105\" class=\"abstract_t\">105</a>]. These findings were supported by two subsequent studies [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/106,107\" class=\"abstract_t\">106,107</a>]. The FDA has since issued a black box warning for the atypical antipsychotics. Prescribing information for all antipsychotics now includes the black box warning. Antipsychotics (typical and atypical) should be used with caution in all elderly patients with dementia, including the critically ill.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> interacts with numerous drugs that are common in the ICU. As an example, drugs with central nervous system (CNS) depressant effects (eg, opioids, sedatives) may enhance the CNS depressant effect of haloperidol.</p><p>Other drug interactions are related to the metabolism of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> via the CYP3A4 and CYP2D6 pathways. These include azole antifungals and <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic azole antifungals (eg, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>), HIV and HCV protease inhibitors, and <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, inhibit CYP3A4, which prolongs <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> activity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> increases CYP3A4 metabolism, which decreases <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> activity. This effect is enhanced because haloperidol increases carbamazepine activity by inhibiting carbamazepine metabolism.</p><p/><p>The rifamycins (eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>) also induce cytochrome P450-mediated oxidative metabolism and decrease <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> activity. Anticholinergics (eg, <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a>, <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a>) increase haloperidol clearance via an unknown mechanism.</p><p>When <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> is used, other drugs that enhance the QTc-prolonging effect of haloperidol (eg, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, <a href=\"topic.htm?path=dronedarone-drug-information\" class=\"drug drug_general\">dronedarone</a>, <a href=\"topic.htm?path=ranolazine-drug-information\" class=\"drug drug_general\">ranolazine</a>, <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a>, high dose <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a>, <a href=\"topic.htm?path=domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">domperidone</a>, <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, fluoroquinolone antibiotics, tricyclic antidepressants, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>) should be avoided. Additional agents are listed in the table (<a href=\"image.htm?imageKey=CARD%2F57431\" class=\"graphic graphic_table graphicRef57431 \">table 2</a>). <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">Metoclopramide</a> may increase haloperidol toxicity and should also not be given concurrently.</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">BARBITURATES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thiopental (Pentothal) and <a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">methohexital</a> (Brevital) are barbiturates that are occasionally used to sedate critically ill patients. Barbiturates produce sedation by binding to the gamma aminobutyric acid (GABA)-receptor complex via a different receptor from benzodiazepines. They commonly cause hypotension and may produce profound cardiovascular and respiratory depression. As a result, the use of barbiturates should be limited to patients not tolerating or responding to other agents. Other undesirable characteristics of barbiturates include prolonged elimination half-lives, induction of the cytochrome p-450 enzyme system, and accumulation of drugs in renal and hepatic dysfunction. Thiopental is no longer manufactured in the United States or Canada. </p><p class=\"headingAnchor\" id=\"H27695579\"><span class=\"h1\">SEVOFLURANE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">Sevoflurane</a>, a polyfluorinated methyl-isopropyl compound, is a volatile inhalational anesthetic that is being evaluated as a potential sedative agent for intensive care unit (ICU) patients. Ninety-five to 98 percent of sevoflurane is eliminated through the lungs, while the remaining 2 to 5 percent undergoes rapid hepatic metabolism to inorganic fluoride and hexafluoroisopropanol (HFIP) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/108\" class=\"abstract_t\">108</a>]. HFIP in the blood is conjugated by glucuronic acid and then secreted by the kidney. </p><p>Potential advantages of <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> as a sedating agent for critically ill ICU patients include the short duration of action and rapid elimination [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/109\" class=\"abstract_t\">109</a>]. Potential disadvantages include fluoride accumulation with prolonged use (especially in patients with impaired renal function) and malignant hyperthermia [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/109\" class=\"abstract_t\">109</a>]. Additionally, sevoflurane undergoes degradation on contact with alkaline carbon dioxide absorbents used to remove carbon dioxide from the circuit, to a potentially nephrotoxic product (trifluoromethyl vinyl ether; Compound A) [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/108\" class=\"abstract_t\">108</a>]. Administration of volatile anesthetic agents in the ICU is not a standard practice; investments in technology and clinician education will be required before sevoflurane can be used as a routine sedative in critically ill patients. (See <a href=\"topic.htm?path=malignant-hyperthermia-clinical-diagnosis-and-management-of-acute-crisis\" class=\"medical medical_review\">&quot;Malignant hyperthermia: Clinical diagnosis and management of acute crisis&quot;</a> and <a href=\"topic.htm?path=susceptibility-to-malignant-hyperthermia-evaluation-and-management\" class=\"medical medical_review\">&quot;Susceptibility to malignant hyperthermia: Evaluation and management&quot;</a>.) &#160;</p><p>A trial randomly assigned 60 mechanically ventilated ICU patients to sedation with <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a>, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, or <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/110\" class=\"abstract_t\">110</a>]. All of the patients received <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> for analgesia, most were relatively young trauma patients, and 47 completed the trial. The median duration of sedation in the sevoflurane group was 50 hours (range 39 to 71 hours). Wake-up time and time to extubation were significantly shorter in the sevoflurane group compared with the propofol or midazolam groups. The study had too few events to conclusively detect differences in ICU length of stay or mortality. &#160;</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h1\">CHOICE OF AGENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No sedative-analgesic agent is sufficiently superior to other agents to warrant its use in all clinical situations. As a result, selection of an agent must be individualized according to patient characteristics and the clinical situation. The etiology of the distress, the expected duration of therapy, potential interactions with other drugs, the desired depth of sedation, and pharmacokinetic modifying factors are important considerations whenever selecting an agent. The selection of sedative analgesics in the critically ill patient is discussed separately. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal#H8\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;, section on 'Selection of an agent'</a>.)</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h1\">COMBINATION THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many clinicians believe that combination therapy using different types of sedatives is best. The rationale is that agitation is often multifactorial and each potential cause deserves a targeted therapy. This notion was supported by a trial that randomly assigned 30 mechanically ventilated patients to receive <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> alone or midazolam plus <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> [<a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/111\" class=\"abstract_t\">111</a>]. Midazolam plus fentanyl maintained sedation level goals better, decreased the dose of the primary agent, added analgesia, and did not appreciably increase the likelihood of prolonged sedation. There were no differences in hemodynamic or respiratory adverse effects. Two patients treated with the combination regimen developed ileus, compared to none with midazolam alone. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Distress due to pain, anxiety, dyspnea, or delirium is common among critically ill patients. Distress may cause ventilator asynchrony and increase sympathetic tone, which may have untoward clinical effects. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Classes of sedative-analgesic medications used to treat distress include opioids, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a>, benzodiazepines, neuroleptics, and, rarely, barbiturates. Pilot studies of the propofol prodrug fospropofol and the volatile anesthetic <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> have been reported. (See <a href=\"#H2\" class=\"local\">'Benzodiazepines'</a> above and <a href=\"#H970065\" class=\"local\">'Analgesics'</a> above and <a href=\"#H11\" class=\"local\">'Antipsychotics'</a> above and <a href=\"#H970645\" class=\"local\">'Propofol'</a> above and <a href=\"#H970932\" class=\"local\">'Dexmedetomidine'</a> above and <a href=\"#H29\" class=\"local\">'Barbiturates'</a> above and <a href=\"#H1252258399\" class=\"local\">'Fospropofol'</a> above and <a href=\"#H27695579\" class=\"local\">'Sevoflurane'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No sedative-analgesic agent is sufficiently superior to other agents to warrant its use in all clinical situations. As a result, selection of an agent must be individualized according to patient characteristics and the clinical situation. The etiology of the distress, the expected duration of therapy, potential interactions with other drugs, the desired depth of sedation, and pharmacokinetic modifying factors are important considerations whenever selecting an agent. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal#H8\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;, section on 'Selection of an agent'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-dependent respiratory and cardiovascular depression are common among sedative-analgesic agents. Most classes of sedative-analgesics also have unique adverse effects. Examples include propylene glycol toxicity and the <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion syndrome. (See <a href=\"#H8\" class=\"local\">'Propylene glycol toxicity'</a> above and <a href=\"#H970882\" class=\"local\">'Propofol infusion syndrome'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/1\" class=\"nounderline abstract_t\">Hansen-Flaschen J. Improving patient tolerance of mechanical ventilation. Challenges ahead. Crit Care Clin 1994; 10:659.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/2\" class=\"nounderline abstract_t\">Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. Effect of analgesic treatment on the physiological consequences of acute pain. Am J Hosp Pharm 1994; 51:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/3\" class=\"nounderline abstract_t\">Kim SH, Stoicea N, Soghomonyan S, Bergese SD. Intraoperative use of remifentanil and opioid induced hyperalgesia/acute opioid tolerance: systematic review. Front Pharmacol 2014; 5:108.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/4\" class=\"nounderline abstract_t\">Rivosecchi RM, Rice MJ, Smithburger PL, et al. An evidence based systematic review of remifentanil associated opioid-induced hyperalgesia. Expert Opin Drug Saf 2014; 13:587.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/5\" class=\"nounderline abstract_t\">Ishii H, Petrenko AB, Kohno T, Baba H. No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in mice. Mol Pain 2013; 9:11.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/6\" class=\"nounderline abstract_t\">Salpeter SR, Buckley JS, Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med 2013; 16:616.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/7\" class=\"nounderline abstract_t\">Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41:263.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/8\" class=\"nounderline abstract_t\">Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006; 34:1326.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/9\" class=\"nounderline abstract_t\">Lonardo NW, Mone MC, Nirula R, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients. Am J Respir Crit Care Med 2014; 189:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/10\" class=\"nounderline abstract_t\">Nelson LE, Guo TZ, Lu J, et al. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 2002; 5:979.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/11\" class=\"nounderline abstract_t\">Deambrogio V, Gatti G, Mongio F, et al. [A case of superficial lymph node tuberculosis]. Minerva Med 1991; 82:507.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/12\" class=\"nounderline abstract_t\">Zecharia AY, Nelson LE, Gent TC, et al. The involvement of hypothalamic sleep pathways in general anesthesia: testing the hypothesis using the GABAA receptor beta3N265M knock-in mouse. J Neurosci 2009; 29:2177.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/13\" class=\"nounderline abstract_t\">Jurd R, Arras M, Lambert S, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J 2003; 17:250.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/14\" class=\"nounderline abstract_t\">Asserh&oslash;j LL, Mosbech H, Kr&oslash;igaard M, Garvey LH. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut&dagger;. Br J Anaesth 2016; 116:77.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/15\" class=\"nounderline abstract_t\">Dziedzic A. Is Propofol Safe For Food Allergy Patients? A Review of the Evidence. SAAD Dig 2016; 32:23.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/16\" class=\"nounderline abstract_t\">Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50:636.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/17\" class=\"nounderline abstract_t\">Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest 1993; 103:557.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/18\" class=\"nounderline abstract_t\">Hug CC Jr, McLeskey CH, Nahrwold ML, et al. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 1993; 77:S21.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/19\" class=\"nounderline abstract_t\">Riker RR, Glisic EK, Fraser GL. Propofol infusion syndrome: difficult to recognize, difficult to study. Crit Care Med 2009; 37:3169.</a></li><li class=\"breakAll\">Diprivan package insert. Astra Zeneca. August 2005.</li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/21\" class=\"nounderline abstract_t\">Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995; 333:147.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/22\" class=\"nounderline abstract_t\">Mirenda J. Prolonged propofol sedation in the critical care unit. Crit Care Med 1995; 23:1304.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/23\" class=\"nounderline abstract_t\">Blakey SA, Hixson-Wallace JA. Clinical significance of rare and benign side effects: propofol and green urine. Pharmacotherapy 2000; 20:1120.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/24\" class=\"nounderline abstract_t\">Nates J, Avidan A, Gozal Y, Gertel M. Appearance of white urine during propofol anesthesia. Anesth Analg 1995; 81:210.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/25\" class=\"nounderline abstract_t\">Ho KM, Ng JY. The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis. Intensive Care Med 2008; 34:1969.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/26\" class=\"nounderline abstract_t\">McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003; 17:235.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/27\" class=\"nounderline abstract_t\">Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007; 62:690.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/28\" class=\"nounderline abstract_t\">Pothineni NV, Hayes K, Deshmukh A, Paydak H. Propofol-related infusion syndrome: rare and fatal. Am J Ther 2015; 22:e33.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/29\" class=\"nounderline abstract_t\">Wong JM. Propofol infusion syndrome. Am J Ther 2010; 17:487.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/30\" class=\"nounderline abstract_t\">Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med 2011; 26:59.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/31\" class=\"nounderline abstract_t\">Fong JJ, Sylvia L, Ruthazer R, et al. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med 2008; 36:2281.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/32\" class=\"nounderline abstract_t\">Crozier TA. The 'propofol infusion syndrome': myth or menace? Eur J Anaesthesiol 2006; 23:987.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/33\" class=\"nounderline abstract_t\">Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 2009; 13:R169.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/34\" class=\"nounderline abstract_t\">Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med 2009; 37:3024.</a></li><li class=\"breakAll\">Lusedra package insert. Eisai R&amp;D management C., Ltd. 10/09.</li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/36\" class=\"nounderline abstract_t\">Candiotti KA, Gan TJ, Young C, et al. A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. Anesth Analg 2011; 113:550.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/37\" class=\"nounderline abstract_t\">Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 2004; 30:2188.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/38\" class=\"nounderline abstract_t\">Buck ML, Willson DF. Use of dexmedetomidine in the pediatric intensive care unit. Pharmacotherapy 2008; 28:51.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/39\" class=\"nounderline abstract_t\">Chen K, Lu Z, Xin YC, et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev 2015; 1:CD010269.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/40\" class=\"nounderline abstract_t\">Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012; 307:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/41\" class=\"nounderline abstract_t\">Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/42\" class=\"nounderline abstract_t\">Adams R, Brown GT, Davidson M, et al. Efficacy of dexmedetomidine compared with midazolam for sedation in adult intensive care patients: a systematic review. Br J Anaesth 2013; 111:703.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/43\" class=\"nounderline abstract_t\">Torbic H, Papadopoulos S, Manjourides J, Devlin JW. Impact of a protocol advocating dexmedetomidine over propofol sedation after robotic-assisted direct coronary artery bypass surgery on duration of mechanical ventilation and patient safety. Ann Pharmacother 2013; 47:441.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/44\" class=\"nounderline abstract_t\">Klompas M, Li L, Szumita P, et al. Associations Between Different Sedatives and Ventilator-Associated Events, Length of Stay, and Mortality in Patients Who Were Mechanically Ventilated. Chest 2016; 149:1373.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/45\" class=\"nounderline abstract_t\">Turunen H, Jakob SM, Ruokonen E, et al. Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Crit Care 2015; 19:67.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/46\" class=\"nounderline abstract_t\">Patanwala AE, Erstad BL. Comparison of Dexmedetomidine Versus Propofol on Hospital Costs and Length of Stay. J Intensive Care Med 2016; 31:466.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/47\" class=\"nounderline abstract_t\">Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial. JAMA 2017; 317:1321.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/48\" class=\"nounderline abstract_t\">Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298:2644.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/49\" class=\"nounderline abstract_t\">Ji F, Li Z, Nguyen H, et al. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation 2013; 127:1576.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/50\" class=\"nounderline abstract_t\">Ji F, Li Z, Young N, et al. Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2014; 28:267.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/51\" class=\"nounderline abstract_t\">MacLaren R, Preslaski CR, Mueller SW, et al. A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their experiences and short-term psychological outcomes. J Intensive Care Med 2015; 30:167.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/52\" class=\"nounderline abstract_t\">Reade MC, Eastwood GM, Bellomo R, et al. Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial. JAMA 2016; 315:1460.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/53\" class=\"nounderline abstract_t\">Zaal IJ, Devlin JW, Peelen LM, Slooter AJ. A systematic review of risk factors for delirium in the ICU. Crit Care Med 2015; 43:40.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/54\" class=\"nounderline abstract_t\">Serafim RB, Bozza FA, Soares M, et al. Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. J Crit Care 2015; 30:799.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/55\" class=\"nounderline abstract_t\">Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54:1136.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/56\" class=\"nounderline abstract_t\">Mueller SW, Preslaski CR, Kiser TH, et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med 2014; 42:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/57\" class=\"nounderline abstract_t\">Gagnon DJ, Riker RR, Glisic EK, et al. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy 2015; 35:251.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/58\" class=\"nounderline abstract_t\">Dasta JF, Kane-Gill SL, Durtschi AJ. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. Ann Pharmacother 2004; 38:1130.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/59\" class=\"nounderline abstract_t\">Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003; 29:201.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/60\" class=\"nounderline abstract_t\">Holliday SF, Kane-Gill SL, Empey PE, et al. Interpatient variability in dexmedetomidine response: a survey of the literature. ScientificWorldJournal 2014; 2014:805013.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/61\" class=\"nounderline abstract_t\">Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg 2008; 106:1784.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/62\" class=\"nounderline abstract_t\">M&ouml;hler H, Richards JG. The benzodiazepine receptor: a pharmacological control element of brain function. Eur J Anaesthesiol Suppl 1988; 2:15.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/63\" class=\"nounderline abstract_t\">Arendt RM, Greenblatt DJ, deJong RH, et al. In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther 1983; 227:98.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/64\" class=\"nounderline abstract_t\">Ziegler WH, Schalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 1983; 16 Suppl 1:63S.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/65\" class=\"nounderline abstract_t\">Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6:89.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/66\" class=\"nounderline abstract_t\">Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/67\" class=\"nounderline abstract_t\">Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/68\" class=\"nounderline abstract_t\">Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104:21.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/69\" class=\"nounderline abstract_t\">Jones C, B&auml;ckman C, Capuzzo M, et al. Precipitants of post-traumatic stress disorder following intensive care: a hypothesis generating study of diversity in care. Intensive Care Med 2007; 33:978.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/70\" class=\"nounderline abstract_t\">Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/71\" class=\"nounderline abstract_t\">Pisani MA, Murphy TE, Araujo KL, et al. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009; 37:177.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/72\" class=\"nounderline abstract_t\">Zaal IJ, Devlin JW, Hazelbag M, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med 2015; 41:2130.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/73\" class=\"nounderline abstract_t\">Litchfield NB. Complications of Intravenous Diazepam - Adverse Psychological Reactions. (An assessment of 16,000 cases). Anesth Prog 1980; 27:175.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/74\" class=\"nounderline abstract_t\">Thurston TA, Williams CG, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg 1996; 83:192.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/75\" class=\"nounderline abstract_t\">Fulton SA, Mullen KD. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil? Am J Gastroenterol 2000; 95:809.</a></li><li class=\"breakAll\">Diazepam injection [Baxter Healthcare Corporation] United States Food and Drug Administration approved prescribing information. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1045 (Accessed on May 12, 2010).</li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/77\" class=\"nounderline abstract_t\">Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med 2002; 346:1253.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/78\" class=\"nounderline abstract_t\">Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001; 21:1140.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/79\" class=\"nounderline abstract_t\">Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest 2005; 128:1674.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/80\" class=\"nounderline abstract_t\">Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med 2000; 343:815.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/81\" class=\"nounderline abstract_t\">Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med 2004; 32:1709.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/82\" class=\"nounderline abstract_t\">Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy 2008; 28:984.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/83\" class=\"nounderline abstract_t\">Barnes BJ, Gerst C, Smith JR, et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy 2006; 26:23.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/84\" class=\"nounderline abstract_t\">Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg 2014; 119:170.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/85\" class=\"nounderline abstract_t\">Kundra P, Velayudhan S, Krishnamachari S, Gupta SL. Oral ketamine and dexmedetomidine in adults' burns wound dressing--A randomized double blind cross over study. Burns 2013; 39:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/86\" class=\"nounderline abstract_t\">Norambuena C, Ya&ntilde;ez J, Flores V, et al. Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study. J Pediatr Surg 2013; 48:629.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/87\" class=\"nounderline abstract_t\">Patanwala AE, Martin JR, Erstad BL. Ketamine for Analgosedation in the Intensive Care Unit: A Systematic Review. J Intensive Care Med 2017; 32:387.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/88\" class=\"nounderline abstract_t\">Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38:419.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/89\" class=\"nounderline abstract_t\">Seem&uuml;ller F, Volkmer E, Vogel T, et al. Quetiapine as treatment for delirium during weaning from ventilation: a case report. J Clin Psychopharmacol 2007; 27:526.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/90\" class=\"nounderline abstract_t\">Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004; 30:444.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/91\" class=\"nounderline abstract_t\">Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45:297.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/92\" class=\"nounderline abstract_t\">Kram BL, Kram SJ, Brooks KR. Implications of atypical antipsychotic prescribing in the intensive care unit. J Crit Care 2015; 30:814.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/93\" class=\"nounderline abstract_t\">Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37:435.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/94\" class=\"nounderline abstract_t\">Avent KM, DeVoss JJ, Gillam EM. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem Res Toxicol 2006; 19:914.</a></li><li class=\"breakAll\">Information for Healthcare Professionals: Haloperidol http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm085203.htm (Accessed on May 12, 2010).</li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/96\" class=\"nounderline abstract_t\">Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/97\" class=\"nounderline abstract_t\">Fernandez F, Holmes VF, Adams F, Kavanaugh JJ. Treatment of severe, refractory agitation with a haloperidol drip. J Clin Psychiatry 1988; 49:239.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/98\" class=\"nounderline abstract_t\">Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother 1995; 29:690.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/99\" class=\"nounderline abstract_t\">Mac Sweeney R, Barber V, Page V, et al. A national survey of the management of delirium in UK intensive care units. QJM 2010; 103:243.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/100\" class=\"nounderline abstract_t\">Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm 1991; 10:456.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/101\" class=\"nounderline abstract_t\">Stern TA. The management of depression and anxiety following myocardial infarction. Mt Sinai J Med 1985; 52:623.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/102\" class=\"nounderline abstract_t\">Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13:128.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/103\" class=\"nounderline abstract_t\">Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119:391.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/104\" class=\"nounderline abstract_t\">Menza MA, Murray GB, Holmes VF, Rafuls WA. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987; 48:278.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/105\" class=\"nounderline abstract_t\">Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/106\" class=\"nounderline abstract_t\">Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/107\" class=\"nounderline abstract_t\">Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176:627.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/108\" class=\"nounderline abstract_t\">Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet 1999; 36:13.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/109\" class=\"nounderline abstract_t\">Bracco D, Donatelli F. Volatile agents for ICU sedation? Intensive Care Med 2011; 37:895.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/110\" class=\"nounderline abstract_t\">Mesnil M, Capdevila X, Bringuier S, et al. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med 2011; 37:933.</a></li><li><a href=\"https://www.uptodate.com/contents/sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects/abstract/111\" class=\"nounderline abstract_t\">Richman PS, Baram D, Varela M, Glass PS. Sedation during mechanical ventilation: a trial of benzodiazepine and opiate in combination. Crit Care Med 2006; 34:1395.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1616 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H32\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H970065\" id=\"outline-link-H970065\">ANALGESICS</a><ul><li><a href=\"#H971743\" id=\"outline-link-H971743\">Opioid analgesics</a></li><li><a href=\"#H971750\" id=\"outline-link-H971750\">Nonopioid analgesics</a></li></ul></li><li><a href=\"#H970645\" id=\"outline-link-H970645\">PROPOFOL</a><ul><li><a href=\"#H970847\" id=\"outline-link-H970847\">Mechanism</a></li><li><a href=\"#H970854\" id=\"outline-link-H970854\">Properties</a></li><li><a href=\"#H970861\" id=\"outline-link-H970861\">Dosage regimens</a></li><li><a href=\"#H970868\" id=\"outline-link-H970868\">Administration</a></li><li><a href=\"#H970875\" id=\"outline-link-H970875\">Adverse effects</a><ul><li><a href=\"#H970882\" id=\"outline-link-H970882\">- Propofol infusion syndrome</a></li><li><a href=\"#H970925\" id=\"outline-link-H970925\">- Drug interactions</a></li></ul></li></ul></li><li><a href=\"#H1252258399\" id=\"outline-link-H1252258399\">FOSPROPOFOL</a></li><li><a href=\"#H970932\" id=\"outline-link-H970932\">DEXMEDETOMIDINE</a><ul><li><a href=\"#H971134\" id=\"outline-link-H971134\">Dosage regimen</a></li><li><a href=\"#H971141\" id=\"outline-link-H971141\">Adverse effects</a><ul><li><a href=\"#H971148\" id=\"outline-link-H971148\">- Drug interactions</a></li></ul></li></ul></li><li><a href=\"#H2\" id=\"outline-link-H2\">BENZODIAZEPINES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Mechanism</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Properties</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Selection</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Dosage regimens</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Adverse effects</a><ul><li><a href=\"#H91918874\" id=\"outline-link-H91918874\">- General</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Propylene glycol toxicity</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Drug interactions</a></li></ul></li></ul></li><li><a href=\"#H2957373\" id=\"outline-link-H2957373\">KETAMINE</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">ANTIPSYCHOTICS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Mechanism</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Properties</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Dosage regimens</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Adverse effects</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Drug interactions</a></li></ul></li></ul></li><li><a href=\"#H29\" id=\"outline-link-H29\">BARBITURATES</a></li><li><a href=\"#H27695579\" id=\"outline-link-H27695579\">SEVOFLURANE</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">CHOICE OF AGENT</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">COMBINATION THERAPY</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/1616|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/79667\" class=\"graphic graphic_table\">- Sedative/analgesic dosage regimens</a></li><li><a href=\"image.htm?imageKey=CARD/57431\" class=\"graphic graphic_table\">- Causes of long QT syndrome</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">Acquired long QT syndrome: Definitions, causes, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bariatric-surgery-intensive-care-unit-management-of-the-complicated-postoperative-patient\" class=\"medical medical_review\">Bariatric surgery: Intensive care unit management of the complicated postoperative patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-use-of-neuromuscular-blocking-agents-in-critically-ill-patients\" class=\"medical medical_review\">Clinical use of neuromuscular blocking agents in critically ill patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignant-hyperthermia-clinical-diagnosis-and-management-of-acute-crisis\" class=\"medical medical_review\">Malignant hyperthermia: Clinical diagnosis and management of acute crisis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-moderate-and-severe-alcohol-withdrawal-syndromes\" class=\"medical medical_review\">Management of moderate and severe alcohol withdrawal syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient\" class=\"medical medical_review\">Pain control in the critically ill adult patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=susceptibility-to-malignant-hyperthermia-evaluation-and-management\" class=\"medical medical_review\">Susceptibility to malignant hyperthermia: Evaluation and management</a></li></ul></div></div>","javascript":null}